AbbVie Inc. (NYSE:ABBV) Shares Acquired by Cordatus Wealth Management LLC

Cordatus Wealth Management LLC increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 4.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,980 shares of the company’s stock after acquiring an additional 642 shares during the period. Cordatus Wealth Management LLC’s holdings in AbbVie were worth $2,840,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ABBV. Centricity Wealth Management LLC acquired a new position in shares of AbbVie in the 4th quarter worth $170,000. Waterfront Wealth Inc. boosted its position in shares of AbbVie by 25.5% in the 4th quarter. Waterfront Wealth Inc. now owns 10,189 shares of the company’s stock valued at $1,811,000 after purchasing an additional 2,071 shares during the period. Forte Capital LLC ADV increased its stake in AbbVie by 0.7% in the 4th quarter. Forte Capital LLC ADV now owns 16,356 shares of the company’s stock worth $2,906,000 after purchasing an additional 111 shares in the last quarter. ING Groep NV raised its holdings in AbbVie by 78.7% during the 4th quarter. ING Groep NV now owns 598,335 shares of the company’s stock worth $106,324,000 after buying an additional 263,557 shares during the period. Finally, O Brien Greene & Co. Inc lifted its stake in AbbVie by 0.9% during the fourth quarter. O Brien Greene & Co. Inc now owns 10,964 shares of the company’s stock valued at $1,948,000 after buying an additional 99 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Up 1.8 %

ABBV stock opened at $200.98 on Friday. The firm has a market cap of $354.80 billion, a PE ratio of 83.74, a PEG ratio of 1.56 and a beta of 0.58. AbbVie Inc. has a 1 year low of $153.58 and a 1 year high of $207.32. The company has a fifty day simple moving average of $180.12 and a 200 day simple moving average of $186.19. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same period last year, the firm posted $2.79 earnings per share. Sell-side analysts anticipate that AbbVie Inc. will post 12.32 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a dividend of $1.64 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.26%. AbbVie’s payout ratio is currently 273.33%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ABBV shares. BMO Capital Markets boosted their price target on shares of AbbVie from $208.00 to $215.00 and gave the company an “outperform” rating in a report on Monday, February 3rd. Truist Financial boosted their target price on shares of AbbVie from $211.00 to $217.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Leerink Partners raised AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 target price for the company in a research report on Friday, November 22nd. Raymond James reissued an “outperform” rating and set a $220.00 price target (up from $218.00) on shares of AbbVie in a research report on Monday, February 3rd. Finally, JPMorgan Chase & Co. decreased their price objective on AbbVie from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $208.35.

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the transaction, the senior vice president now owns 6,983 shares of the company’s stock, valued at $1,202,751.92. The trade was a 20.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.25% of the company’s stock.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.